Probiotics may ease radiation-related diarrhea in gynecologic cancer care
A review reports improvements in bowel side effects, mainly during cervical and endometrial cancer treatment, while cancer-control and survival questions remain unanswered.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
Across the included trials, probiotics were reported to reduce radiation-related diarrhea and the need for antidiarrheal medicines. Most evidence concerned cervical and endometrial cancer treatment. The review does not show that these products improve cancer control or survival, and prebiotics alone showed little benefit in the studies summarized.
Formulations, doses and outcomes varied, preventing a pooled analysis. The abstract does not give effect sizes or trial-specific comparison conditions, and it identifies unresolved safety questions in immunocompromised populations.
Why products cannot be treated alike
The reviewers assessed treatment side effects, bowel outcomes and other endpoints, but differences between studies led them to summarize results narratively. The findings therefore do not identify a standardized probiotic product with a predictable benefit.
The limits of the outcomes
Some studies found reduced gut permeability without a change in microbial composition. No trials examined survival or chemotherapy and immunotherapy outcomes. Adverse events were uncommon, but those observations do not settle safety for every cancer population.
The original publication
Assessment of probiotic and prebiotic use in gynecologic cancer patients: a systematic review.
Chalif J, Morton M, Haight P et al.
Am J Obstet Gynecol · 2026
- PubMed ID
- 41072704
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.